• black-back-closed-envelope-shape
  • White Instagram Icon
  • White Facebook Icon
  • White LinkedIn Icon

Copyright ©2019 by Sanomics Limited. All rights reserved.


The pBRAF V600ETM test screens for the presence of BRAF V600E mutation in blood specimens using droplet digital PCR technology. The test targets lung, thyroid, colorectal and melanoma and it is useful for assessing whether the indicated therapies would be useful. It is suggested that if the test results are positive, dabrafenib and trametinib can be used as targeted therapy.


Patients who are treatment-naive.


Sample types: Blood


Turnaround time: 2-3 working days upon sample arrival

Why use BRAF V600ETM?

Affordable price


2-3 working days

High Accuracy

  • Specificity: 99.96%

  • Sensitivity: >99.9%


Only requires ONE streck tube (10mL) of body fluid

Types of Targeted Tumors